HLS Therapeutics (TSE:HLS) Price Target Raised to C$5.00 at Raymond James

HLS Therapeutics (TSE:HLS) had its price objective boosted by Raymond James from C$4.00 to C$5.00 in a report published on Friday,BayStreet.CA reports.

Separately, Stifel Nicolaus lowered their price target on HLS Therapeutics from C$3.75 to C$3.25 in a report on Tuesday, August 13th.

HLS Therapeutics Trading Up 2.3 %

TSE:HLS opened at C$3.50 on Friday. The stock’s 50 day moving average price is C$3.54 and its 200 day moving average price is C$3.48. HLS Therapeutics has a 52 week low of C$3.00 and a 52 week high of C$5.48. The company has a market capitalization of C$111.27 million, a P/E ratio of -3.47 and a beta of 1.07. The company has a debt-to-equity ratio of 100.44, a quick ratio of 1.01 and a current ratio of 2.02.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.